How effective is rasagiline in patients with early-stage Parkinson's disease?

Parkinson's disease is a degenerative disease of the nervous system. Early patients often experience symptoms such as bradykinesia and rigidity. As a drug for the treatment of Parkinson's disease, rasagiline's efficacy in early-stage patients has attracted much attention.

Rasagiline reduces the degradation of dopamine in the brain by blocking the activity of monoamine oxidaseB (MAO-B) in the central nervous system, thereby increasing the dopamine content in the striatum. This mechanism allows rasagiline to show significant efficacy in improving symptoms such as bradykinesia and rigidity in patients with Parkinson's disease. Especially for early-stage patients, rasagiline can effectively alleviate the disease and improve the patient's quality of life.

For patients with early-stage Parkinson's disease, rasagiline can be used not only alone, but also in combination with levodopa. Research shows that this combination can significantly enhance efficacy and better control the symptoms of Parkinson's disease. This is because rasagiline enhances the effects of levodopa while reducing its side effects, allowing patients to achieve more lasting and stable symptom improvement.

Rasagiline has a favorable safety and tolerability profile in early-stage patients. Its side effects are relatively minor, and common side effects such as headache and dizziness are usually mild and can be alleviated by adjusting the dosage of the drug or combining it with other drugs. This makes rasagiline a safe and effective treatment option for patients with early-stage Parkinson's disease.

A Phase III clinical trial calledADAGIO confirmed the efficacy of rasagiline in early-stage Parkinson's disease. The 18-week study included 1,176 patients from 14 different countries and regions, all of whom were in the early stages of Parkinson's disease. Research results show that rasagiline can delay the progression of patients' disease, and its effects have reached a significant level in multiple testing test projects.